

ACoP8 October 16, 2017

Quantification of Covariate Effects for Labeling

Points to Consider when Making Inferences
about Covariates

Marc R. Gastonguay, Ph.D. FISoP



Informing the Drug Label: Dosage and Administration


----- DOSAGE AND ADMINISTRATION-----

Indication	Starting Dose	Target Dose	Maximum Dose
MDD (2.1)	37.5 -75 mg/day	75 mg/day	225 mg/day
GAD (2.2)	37.5 -75 mg/day	75 mg/day	225 mg/day
SAD (2.3)	75 mg/day	75 mg/day	75 mg/day
PD (2.4)	37.5 mg/day	75 mg/day	225 mg/day

- Take once daily with food (2). Capsules should be taken whole; do not divide, crush, chew, or dissolve (2).
- When discontinuing treatment, reduce the dose gradually (2.8, 5.7).
- Renal impairment: reduce the total daily dose by 25% to 50% in patients with renal impairment. Reduce the total daily dose by 50% or more in patients undergoing dialysis or with severe renal impairment (2.6).
- Hepatic impairment: reduce the daily dose by 50% in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment or hepatic cirrhosis, it may be necessary to reduce the dose by more than 50% (2.6).

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020699s107lb1.pdf


Informing the Drug Label: Special Populations



Abbreviations: ODV, O-desmethylvenlafaxine; AUC, area under the curve; Cmax, peak plasma concentrations;
*Similar effect is expected with strong CYP2D6 inhibitors

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020699s1071b1.pdf


Informing the Drug Label: Drug Interactions



Abbreviations: ODV, O-desmethylvenlafaxine; AUC, area under the curve; Cmax, peak plasma concentrations; EM's, extensive metabolizers; PM's, poor metabolizers

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020699s1071b1.pdf

Informing the Drug Label: Special Populations (zoom-in)



https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020699s1071b1.pdf

- Dedicated Clinical Pharmacology Studies

- Single clinical trial with primary goal of assessing covariate effect
- Randomization, Stratification, Test and Reference Control
- Sample size justification based on expected power
- Typically, otherwise healthy volunteers
- Extensive PK sampling and simple data analysis (NCA)


8.6 Age and Gender

A population pharmacokinetic analysis of 404 Effexor-treated patients from two studies involving both twice daily and three times daily regimens showed that dose-normalized trough plasma levels of either venlafaxine or ODV were unaltered by age or gender differences. Dosage adjustment based on the age or gender of a patient is generally not necessary [*see Dosage and Administration (2.6)*] (see Table 15).

- Population PK(PD) Studies

- Often pooled data – cross-study comparisons
- Covariate effect assessment is not primary goal
- Typically no randomization, stratification, or control for covariates
- Target patient population
- Model-based analysis

Correlation and Collinearity



Covariate effects to be included in model should be independent, e.g. they carry unique information.

Rule of thumb:
Be cautious when $|\text{corr. coef.}| > 0.3$

See:

Pharmaceutical Research, Vol. 16, No. 5, 1999

The Effect of Collinearity on Parameter Estimates in Nonlinear Mixed Effect Models

Peter L. Bonate^{1,2}

Appropriate Inference About Covariates?

Table III (continued)

Model	Question	Equation	Objective Function	Conclusion (Significance = Yes)
Model 15	Does condition (Healthy/asthmatic) affect the volume of distribution (V2) (LINEAR MODEL)?	$TVKA = \theta (1)$ $TVCL = \theta (2)$ $TVV2 = \theta (3) * COND + \theta (4) * (1 - COND)$ $\theta (1) = 4.42 \text{ h}^{-1}$ $\theta (2) = 392 \text{ L/h}$ $\theta (3) = 1170 \text{ L}$ $\theta (4) = 1510 \text{ L}$	-9603	No
Model 16	Does condition (Healthy/asthmatic) affect the clearance (POWER MODEL)?	$TVKA = \theta (1)$ $TVCL = \theta (2) * \theta (3) ** COND$ $TVV2 = \theta (4)$ $\theta (1) = 4.42 \text{ h}^{-1}$ $\theta (2) = 363 \text{ L/h}$ $\theta (3) = 468$ $\theta (4) = 1720 \text{ L}$	-240	No
Model 17	Does condition (Healthy/asthmatic) affect the clearance (LINEAR MODEL)?	$TVKA = \theta (1)$ $TVCL = \theta (2) * COND + \theta (3) * (1 - COND)$ $(TVV2 = \theta (4))$ $\theta (1) = 4.42 \text{ h}^{-1}$ $\theta (2) = 384 \text{ L/h}$ $\theta (3) = 438 \text{ L/h}$ $\theta (4) = 1180 \text{ L}$	-9598	No
Model 18	Does weight affect clearance and volume of distribution (POWER MODEL)?	$TVCL = \theta (2) * (WT/75) ** \theta (3)$ $TVV2 = \theta (4) * (WT/75) ** \theta (5)$ $\theta (2) = 393 \text{ L/h}$ $\theta (3) = 0.56$ $\theta (4) = 1220 \text{ L}$ $\theta (5) = 1.28$	-9738	Yes

Appropriate Inference About Covariates?

Covariate Effects:

Creatinine clearance was the most significant covariate on [REDACTED] clearance. The clinical importance of this finding is unknown, since less than 2% of [REDACTED] dose is excreted in the urine. This may be an artifact of the data as the current analysis data set did not include patients with moderate or severe renal impairment. Weight, age and sex were not significant covariates and, therefore, require no dose adjustment.

Statement of the Problem

How to inform labeling given sparse population PK(PD) data and model-based analyses?

- Independent (marginal) inferences about each covariate
- Accurate estimation of covariate effect magnitude
- Precision of covariate effect estimate


Different Objectives of Covariate Model Development

- Understand causes of variability and apply the knowledge
 - For better clinical therapeutic use (dosing, adjustment, labeling)
 - To allow for better control in clinical trials
 - In other words, make causal inferences about covariate effects from modeling results
- Improve predictions of the dependent variable
 - For subjects in the current data set
 - For simulation of future studies
 - For future patients

Different Objectives of Covariate Model Development

- Understand causes of variability and apply the knowledge
 - For better clinical therapeutic use (dosing, adjustment, labeling)
 - To allow for better control in clinical trials
 - In other words, make causal inferences about covariate effects from modeling results
- Improve predictions of the dependent variable
 - For subjects in the current data set
 - For simulation of future studies
 - For future patients

Inferences Based on Posterior Distribution of Effect



First, define effect magnitude likely to be clinically important (e.g. greater than +/- 20% of null value)


Clinically Important: Entire 95% interval of posterior distribution for covariate effect lies within clinically important region (always SS)

Not Clinically Important: Entire 95% interval of posterior distribution for covariate effect lies within clinically unimportant region. May be important in combination with other effects. (NSS or SS)

Insufficient Information: 95% interval of posterior distribution for covariate effect spans across values of covariate effect that are both clinically important and unimportant. (NSS or SS)

Or... Probabilistic Approach: Quantitatively describe probability of being clinically important using posterior distribution and reference range.

Estimation of Effect Magnitude and Precision vs. Stepwise P-Value



Summary of 42 population analyses (32 PK, 10 PD)

A Purpose-Driven Parsimony Principle

*“When competing hypotheses are **equal in other respects**, select the hypothesis that introduces the fewest assumptions and postulates the fewest entities while still **sufficiently answering the question**. ”*

-Occam's razor

- Stepwise p-value reduced models do not allow for inferences about “non-significant” covariate effects and result in biased standard errors and point estimates. They do not **sufficiently answer the question** about clinical importance of covariate effects.
- For the purpose of making inferences about covariate effects, a model which includes the covariates of interest is the most parsimonious model.

Pre-Specified Covariate Plan

Covariate	Model Parameters	Rationale
Weight	CL, V1, Q, V2	Clinical interest
Age	CL	Clinical interest
Race	CL, V1	Clinical interest. Bridging goal.
Disease State Type	CL	Clinical interest
Child-Pugh Score	CL	Clinical interest. Prior knowledge of hepatic elimination mechanism; CYP3A4
Drug X Interaction	CL	Clinical interest. Known CYP3A4 inhibitor and common con-med
etc...		

“The data analyst knows more than the computer... failure to use that knowledge produces inadequate data analysis”.

- Henderson and Velleman. Building multiple regression models interactively. 1981, *Biometrics* 37: 391–411.

References (1)

- Altman, D. G. and P. K. Andersen. 1989. Bootstrap investigation of the stability of a Cox regression model. *Statistics in Medicine* 8: 771–783.
- Agoram, B., Heatherington, A.C., Gastonguay, M.R.. Development and Evaluation of a Population Pharmacokinetic- Pharmacodynamic Model of Darbepoetin Alfa in Patients with Nonmyeloid Malignancies Undergoing Multicycle Chemotherapy. *AAPS PharmSci Vol.:* 8, No.: 3, 2006
- Bies RR, Muldoon MF, Pollock BG, Manuck S, Smith G, Sale ME. A genetic algorithm-based, hybrid machine learning approach to model selection. *J Pharmacokinet Pharmacodyn.* 2006 Apr;33(2):195-221. Epub 2006 Mar 28.
- Bonate, P. L.. The effect of collinearity on parameter estimates in nonlinear mixed effect models (article). *Pharmaceutical Research.* 1999 Volume 16 Number 5 Pages 709-717.
- Burnham KP, Anderson DR. *Model selection and multimodel inference: A practical information-theoretic approach.* 2nd ed. New York: Springer-Verlag, 2002.
- Copas, J. B. 1983. Regression, prediction and shrinkage (with discussion). *Journal of the Royal Statistical Society, Series B* 45: 311–354.
- Derksen, S. and H. J. Keselman. 1992. Backward, forward and stepwise automated subset selection algorithms: frequency of obtaining authentic and noise variables. *British Journal of Mathematical and Statistical Psychology* 45: 265–282.
- Gastonguay, MR. A Full Model Estimation Approach for Covariate Effects: Inference Based on Clinical Importance and Estimation Precision. *The AAPS Journal*; 6(S1), Abstract W4354, 2004.
- Gastonguay, M.R. and Kowalski K.G. Full Covariate Models and WAM Algorithm. *AAPS Webinar.* April 14, 2010. <http://mediaserver.aapspharmaceutica.com/meetings/webinars/archives.pdf>
- Gelman, A. and Carlin, J. B. and Stern, H. S. and Rubin, D. B. *Bayesian data analysis (book).* Chapman & Hall/CRC, 2004, New York.
- Han, Phey Yen and Kirkpatrick, Carl M J and Green, Bruce. Informative study designs to identify true parameter-covariate relationships (article). *J Pharmacokinet Pharmacodyn.* 2009. 36 (2), 147-63.
- Harrell, F.E. *Regression Modeling Strategies.* 2001; Springer-Verlag. NY.

References (2)

- Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med*. 1996;15(4):361-387.
- Hastie, T. and Tibshirani R. and Friedman, J. H. The elements of statistical learning: data mining, inference, and prediction : with 200 full-color illustrations (book). Springer, 2001. New York.
- Henderson and Velleman. Building multiple regression models interactively. 1981, *Biometrics* 37: 391–411.
- Hu, C., Zhang, J. and Zhou, H. Confirmatory analysis for phase III population pharmacokinetics. *Pharm Stat*. 2011 Jan-Feb;10(1):14-26.
- Hurvich, C. M. and Tsai. 1990. The impact of model selection on inference in linear regression. *American Statistician* 44: 214–217.
- Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. *Pharm Res* 1998; 15(9):1463-1468.
- Jonsson EN, Karlsson MO. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. *Comput Methods Programs Biomed* 1999; 58(1):51-64.
- Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. *Clin Pharmacol Ther* 82:17–20
- Kastrissios H., Rohatagi, S, Moberly J, Truitt K, Gao Y, Wada R, Takahashi M., Kawabata K. , and Salazar D. Development of a Predictive Pharmacokinetic Model for a Novel Cyclooxygenase-2 Inhibitor. *J Clin Pharmacol* 2006;46:537-548.
- Knebel W, Tammara B, Udata C, Comer G, Gastonguay MR, Meng X. Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years. *J Clin Pharmacol*. 2011 Mar;51(3):333-45. Epub 2010 May 19.
- Kowalski KG, Hutmacher MM. Efficient Screening of Covariates in Population Models Using Wald's Approximation to the Likelihood Ratio Test. *J. Pharmacokinetic Pharmacodyn* 2001; 28(3):253-275.
- Lunn DJ. Automated covariate selection and Bayesian model averaging in population PK/PD models. *J Pharmacokinetic Pharmacodyn*. 2008 Feb;35(1):85-100. Epub 2007 Nov 8.
- Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects. *J Pharmacokinetic Biopharm* 1992; 20(5):511-528.

References (3)

- Mantel, Nathan. 1970. Why stepdown procedures in variable selection. *Technometrics* 12: 621–625.
- Miller AJ. *Subset Selection in Regression*. Vol 40. 1st ed. London, UK: Chapman & Hall; 1990.
- Ravva P, Gastonguay MR, French JL, Tensfeldt TG, Faessel HM. Quantitative Assessment of Exposure-Response Relationships for the Efficacy and Tolerability of Varenicline for Smoking Cessation. *Clin Pharmacol Ther*. 2010 Jan 27. [Epub ahead of print].
- Ravva P, Gastonguay MR, Tensfeldt TG, Faessel HM. Population pharmacokinetic analysis of varenicline in adult smokers. *Br J Clin Pharmacol*. 2009 Nov;68(5):669-81.
- Ribbing J, Jonsson EN. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. *J Pharmacokinetic Pharmacodyn*. 2004;31:109 - 134.
- Riggs MM, Bergsma TT, Rogers JA, Gastonguay MR, Subramanian GM, Chen C, Devalaraja M, Corey AE, Sun H, Yu J, Stein DS. Population Pharmacokinetics and Exposure-Response of Albinterferon Alfa-2b. *J Clin Pharmacol*. 2011 May 6.
- Roecker, Ellen B. 1991. Prediction error and its estimation for subset—selected models. *Technometrics* 33: 459–468.
- Rohatagi S, Arya V., Zech K., Nave R., Hochhaus G., Jensen B. K. and Barrett J. S. Population Pharmacokinetics and Pharmacodynamics of Ciclesonide. *J. Clin. Pharmacol*. 2003; 43; 365.
- Sale, M. Unsupervised machine learning based model building in NONMEM. (presentation at 2000 ECPAG meeting).
- Senn, S. Some considerations concerning covariates in clinical trials. PAGE 19 (2010) Abstr 1936 [www.page-meeting.org/?abstract=1936]
- Sribney B. Problems with stepwise regression. <http://www.stata.com/support/faqs/stat/stepwise.html>
- Steyerberg EW, Eijkemans MJ, Habbema JD. Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. *J Clin Epidemiol*. October 1999;52(10):935-942.
- Steyerberg EW, Eijkemans MJ, Harrell FE, Jr., Habbema JD. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. *Stat Med*. 2000;19(8):1059-1079.

References (4)

- Su F, Nicolson SC, Gastonguay MR, Barrett JS, Adamson PC, Kang DS, Godinez RI, Zuppa AF. Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. *Anesth Analg*. 2010 May 1;110(5):1383-92.
- Tibshirani, Robert. 1996. Regression shrinkage and selection via the lasso. *Journal of the Royal Statistical Society, B Series* 58: 267–288. *Biopharm* 1994; 22(2):165-177.
- Vach K, Sauerbrei W, Schumacher M. Variable selection and shrinkage: comparison of some approaches. *Statistica Neerlandica*. 2001;55(1):53-75.
- Wade JR, Beal SL, Sambol NC. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis. *J Pharmacokinet*
- Wählby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. *J Pharmacokinet Pharmacodyn* 2001; 28(3):231-252.
- Wakefield J, Bennett J. The Bayesian Modeling of Covariates for Population Pharmacokinetic Models. *J Am Stat Assoc*. 1996;91:917- 927.
- Wählby U, Jonsson EN and Karlsson MO *AAPS PharmSci* 2002; 4 (4) article 27. Comparison of Stepwise Covariate Model Building Strategies in Population Pharmacokinetic-Pharmacodynamic Analysis.